PLF Pharma is the trading name for Hempire Limited, a UK owned and registered company. Operating from a Home Office approved facility in the UK the company holds one of the few Schedule 1 Licenses issued by The Home Office for high THC cannabis; in addition they also have a low THC Cannabis Licence (industrial Hemp).
Since 2015, three years before medical cannabis was legalised in the UK, PLF Pharma has been focused on providing responsibly produced medical cannabis products to cGMP (previously eu-GMP) standards. PLF Pharma work closely with the NHS, Kings College London and other partners to build a framework that allows the company to produce the highest quality active pharmaceutical ingredients to help shape the future of medicinal cannabis in the UK and to reduce the friction during patient access.
Together with our strategic partners, our primary focus is to develop, produce and distribute medicinal products to consistent standards of quality, safety and efficacy. Through clinical trials, research and operating ethics, we aim to develop and manufacture industry leading medicinal products for patients with an unmet need.
PLF Pharma has a Home Office approved, carbon neutral facility in the north of England powered by two 600KW wind turbines and a 30KW array of photovoltaic panels. This will serve as a model for larger, environmentally sustainable facilities moving forward as part of our phased expansion. This will be the first carbon neutral, EU-GMP cultivation and post processing facility in Europe.